News & Events
Successful FDA Audit of AccelLAB:
Dr. Guy Leclerc, president and CEO, is pleased to announce that AccelLAB was successfully audited by the Food and Drug Administration (FDA, Department of Health and Human Services, International Operations Branch, Rockville, MD). The purpose of this inspection was to perform a routine bioresearch monitoring (BIMO) in order to determine if AccelLAB’s facilities and operations were in accordance with FDA Regulations on Good Laboratory Practice (GLP), 21 CFR Part 58. This audit was conducted by the US Food and Drug Administration and representatives from Health Canada as well as the Standards Council of Canada.
Following the inspections, the auditors concluded that AccelLAB runs in full conformity with FDA Good Laboratory Practice. In fact, AccelLAB was complimented for its high level of compliance to GLP. Along with diligence and competitiveness, GLP compliance represents one of the most important quality aspects of our organization. AccelLAB strives to meet the highest expectations of its sponsors and intends to maintain this high level of quality in the future, ensuring the continued success of its research activities.
GRIBOI 2013, Boston, Massachusetts